Several other equities analysts have also commented on the company. HSBC reaffirmed a buy rating and issued a GBX 2,700 ($35.28) price target (up previously from GBX 2,650 ($34.63)) on shares of Genus in a research note on Monday, March 11th. Liberum Capital raised Genus to a buy rating and upped their price target for the company from GBX 2,400 ($31.36) to GBX 2,500 ($32.67) in a research note on Tuesday, March 5th. Finally, Kepler Capital Markets raised Genus to a buy rating and upped their price target for the company from GBX 2,475 ($32.34) to GBX 2,630 ($34.37) in a research note on Thursday, December 6th.
LON GNS opened at GBX 2,226 ($29.09) on Monday. The firm has a market cap of $1.44 billion and a price-to-earnings ratio of -206.11. The company has a current ratio of 2.08, a quick ratio of 1.32 and a debt-to-equity ratio of 22.58. Genus has a fifty-two week low of GBX 2,090 ($27.31) and a fifty-two week high of GBX 2,998 ($39.17).
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.